-

Dexcom Publishes Annual Sustainability Report

  • Report advances Dexcom’s environmental, social, and governance (ESG) transparency by providing new disclosures including company’s first Sustainability Accounting Standards Board (SASB) index

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its third annual Sustainability Report. This report highlights Dexcom’s mission-driven efforts and provides updates on the environmental, social, and governance (ESG) initiatives progressing across the organization.

“At Dexcom, we remain focused on how we can better serve our stakeholders, including customers, employees, caregivers, investors, and communities,” said Kevin Sayer, chairman, president and CEO of Dexcom. “From broadening global access to our technology, advocating for the diabetes community, and supporting and developing our passionate and diverse employee base, we are proud of our accomplishments while embracing the need for continued progress toward the ambitious mission that motivates us.”

Dexcom’s sustainability initiatives are overseen by the Board of Directors and integrated as foundational elements of the company’s business strategy and mission. The annual report is framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.

Highlights from this year’s report include:

  • Publishing Dexcom’s first Sustainability Accounting Standards Board (SASB) index to improve ESG disclosure
  • Simplifying and expanding access to Dexcom CGM technology through payer negotiations, new product introductions, and clinical outcomes
  • Providing incremental disclosure around employee engagement and the makeup of Dexcom’s workforce
  • Committing to greater visibility on the organization’s emissions profile and climate-related disclosure

Dexcom’s Annual Sustainability Report can be found on the company’s investor relations site at the following link: Dexcom Annual Sustainability Report. All data in the report reflects calendar year 2021, unless noted otherwise.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From DexCom, Inc.

Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands, and Spain with further EMEA country launches planned for 2026. Guided directly by H...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM sy...

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as...
Back to Newsroom